Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 12/20 | 0.79 |
| ▸ | CHRNA4 | P43681 | 12/20 | 0.79 |
| ▸ | CHRNB4 | P30926 | 9/20 | 0.79 |
| ▸ | CHRNA3 | P32297 | 9/20 | 0.79 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.43 |
| ▸ | CHRNG | P07510 | 2/20 | 0.43 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.43 |
| ▸ | CHRND | Q07001 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6390297 | 0.98 | CHRNB2 (0.76) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL4405016 | 0.88 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL4407132 | 0.86 | CHRNB2 (0.96) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL20757478 | 0.78 | CHRNB2 (0.63) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL6391560 | 0.76 | CHRNB2 (0.79) | CHRNB2CHRNA4CHRNB4CHRNA3HTR2C | |
| SCHEMBL8251207 | 0.76 | CHRNB2 (0.79) | CHRNB2CHRNA4CHRNB4CHRNA3HTR2C | |
| SCHEMBL5769118 | 0.76 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3HTR2C | |
| SCHEMBL2061289 | 0.76 | CHRNB2 (0.79) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL1822160 | 0.76 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL20438926 | 0.76 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648872-A2 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | Pfizer Products Inc. (US) | 2006-04-26 | — | — | EP | claimed |
| WO-2005007630-A2 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2005-01-27 | — | — | WO | claimed |
| US-20050020616-A1 | Aryl fused azapolycyclic compounds | PFIZER INC | 2005-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020616-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN2B | CHRNB2 249/4885CHRNA4 157/4885CHRNB4 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.